Publication | Closed Access

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

RheumatologyIl-23 InhibitorAutoimmune DiseaseSclerodermaSystemic Lupus Erythematosus TreatmentLupusRheumatic DiseasesImmunologyClinical TrialsAutoimmunityInflammatory Rheumatic DiseaseImmunologic DiseasePhase 2ImmunotherapyMedicineRheumatoid Arthritis